Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 1561-1570 Newer>

BusinessWeek December 6, 2004 Gene G. Marcial	Why There's New Life At Bioenvision Bioenvision's leading product, Clofarabine, for treating leukemia in children, may get Food & Drug Administration approval soon. Is the stock a good buy?
The Motley Fool November 24, 2004 Charly Travers	A Blockbuster Drug Gains Approval Biogen IDEC and Elan announced that Tysabri had been approved by the FDA for the treatment of muliple sclerosis (MS). Tysabri has long been regarded as a drug that will generate a whopping level of sales.
The Motley Fool November 24, 2004 Tom Engle	A Small-Cap Market Beater Medical Action Industries is primed for success. Investors transfixed on earnings and sales growth might miss other signs that the company is growing in value.
The Motley Fool November 23, 2004 Brian Gorman	AstraZeneca Buys Into Cambridge Antibody Cambridge Antibody scored a new alliance, although the deal threatens to make it a house divided.
The Motley Fool November 23, 2004 Charly Travers	Don't Be Afraid of Biotech You don't need to be a scientist to invest in this high-growth sector.
Bio-IT World November 19, 2004 Mark D. Uehling	Safety Last? Antiquated reporting of adverse events in clinical trials is costing pharma billions and forcing it to seek new pharmacovigilance solutions.
Bio-IT World November 19, 2004 Spruill & Coulter	Intellectual Property: Following Festo Considered one of the most important patent decisions in history, the Supreme Court's Festo ruling has great significance for biotech inventions.
Bio-IT World November 19, 2004 John Russell	Sourcebook: Matters of Interpretation Michael O'Connell talks about trends in microarray and mass-spec data analysis and Insightful Corp.'s recent deal with visualization specialist Spotfire.
Bio-IT World November 19, 2004 Malorye A. Branca	Engines of Discovery It's what every biotech startup promises but few deliver, a turbo-charged discovery engine. Every now and then, however, a new company with fresh ideas starts hitting home runs.
Bio-IT World November 19, 2004 Hoffer & Nambiar	Mirus Index Heads South Overall, companies in the Mirus Index declined in the third quarter of 2004.
<Older 1561-1570 Newer> Return to current articles.